Results 81 to 90 of about 2,403,288 (173)

Spotlight on nilotinib in the treatment of chronic myelogenous leukemia

open access: yes, 2014
Stephen Harnicar, Sherry Mathew Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA Abstract: Nowhere has targeted therapy been more successful in the hematologic malignancy arena than chronic myelogenous leukemia (CML). By
Harnicar S, Mathew S
core  

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)

open access: yesActa Medica, 2003
The publication provides an up-to-date review of the significance of cytogenetic abnormalities in chronic myelogenous leukemia (CML) and the development of a promising agent with specific molecular target against tyrosine kinase, product of the BCR-ABL ...
Ladislav Chrobák, Jaroslava Voglová
doaj   +1 more source

The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines

open access: yesHaematologica, 2006
We evaluated the effect of the human immunodeficiency virus (HIV) protease inhibitor saquinavir on the imatinib-sensitive and imatinib-resistant chronic myelogenous leukemia cell lines.
F Timeus   +6 more
doaj  

Curcumin induces selective packaging of miR-21 in exosomes released by Chronic Myelogenous Leukemia cells

open access: yes, 2015
Curcumin induces selective packaging of miR-21 in exosomes released by Chronic Myelogenous Leukemia ...
Marzia Pucci   +6 more
core  

Targeting Chronic Myelogenous Leukemia with Imatinib and Glycyrrhizic Acid Combination Therapy

open access: yes, 2020
Examining the efficacy of an imatinib and glycyrrhizic acid combination treatment on chronic myelogenous leukemia cell lines.
Adir Mohaban, Olga N. Uchakina
core  

Ponatinib: An oral tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome -- positive acute lymphoblastic leukemia [PDF]

open access: yes, 2013
Ponatinib (Iclusig; Ariad Pharmaceuticals) is an oral tyrosine kinase inhibitor (TKI) that was approved by FDA on December 14, 2012, for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myelogenous leukemia ...
Feret, Brett
core   +1 more source

Chronic myelogenous leukemia terminating in acute megakaryoblastic leukemia. Case report

open access: yes, 1998
A case of chronic myelogenous leukemia (CML) terminating in acute megakaryoblastic leukemia (AMKL) is here presented. Megakaryoblasts were identified by the presence of platelet peroxidase in the bone marrow as well as in pleural effusion and ascites ...
Bai, M.   +5 more
core  

"Transformation of chronic myelogenous leukemia to Multiple Myeloma: A case report " [PDF]

open access: yesActa Medica Iranica, 2003
Chronic myelogenous leukemia (CML) is a stem cell disorder sometimes associated with lymphoproliferative disorders. CML may precede a lymphoproliferative disorder.
"Ghavamzadeh A   +5 more
doaj  

Applications of Microarray Technology to Acute Myelogenous Leukemia

open access: yes, 2009
Microarray technology is a powerful tool, which has been applied to further the understanding of gene expression changes in disease. Array technology has been applied to the diagnosis and prognosis of Acute Myelogenous Leukemia (AML).
Mahadeo A. Sukhai   +4 more
core  

Chronic Myelogenous Leukemia Guidelines

open access: yes, 2007
Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease.
_ _
core   +1 more source

Home - About - Disclaimer - Privacy